







14th International Congress of Inborn Errors of Metabolism 2021

'Transforming Rare Disorders'

21-24 November 2021



AEDT	SUNDAY 21 NOVEMBER 2021			AEDT	IST	CET (Saturday)	CST (Saturday)		
07:00	Opening and Welcome Address Including welcome by the Honourable Minister Greg HUNT MP <i>Minister for Health and Aged Care, Australia</i>			07:00	1:30	21:00	14:00		
NEW APPROACHES TO DIAGNOSIS									
07:30-08:12	Diagnoses and discoveries: Insights from the NIH Undiagnosed Diseases Program Dr William A. GAHL <i>National Human Genome Research Institute</i>			07:30	2:00	21:30	14:30		
08:12-08:30	Novel disorders discovered by whole genome sequencing Professor Shigeo KURE <i>Tohoku University School of Medicine</i>			08:12	2:42	22:12	15:12		
08:30-09:00	Multi-Omic approaches aid identification of cryptic variants underlying mitochondrial disorders Professor David THORBURN <i>Murdoch Children's Research Institute</i>			08:30	3:00	22:30	15:30		
09:00-09:18	Metabolomics Professor Bart GHESQUIÈRE <i>KU Leuven Metabolomics Expertise Center</i>			09:00	3:30	23:00	16:00		
09:18-09:45	Metabolics and genetics: Systems biology? Professor Henri Gerrit (Han) BRUNNER <i>Radboud University Nijmegen Medical Center and Maastricht University Medical Center</i>			09:18	3:48	23:18	16:18		
09:45-10:45	POSTER VIEWING BREAK			09:45	4:15	23:45	16:45		
SCREENING									
10:45-11:15	Reproductive genetic carrier screening for families with inborn errors of metabolism Professor Edwin KIRK <i>Sydney Children's Hospital, New South Wales Health Pathology Randwick Genomic Laboratory</i>			10:45	5:15	0:45 (Sunday)	17:45		
11:15-11:45	Population based newborn screening - The future Associate Professor Veronica WILEY <i>Children's Hospital, Westmead</i>			11:15	5:45	1:15	18:15		
11:45-12:11	Outcome studies in newborn screening: How lessons learned can guide screening strategy Professor Stefan KÖLKER <i>Heidelberg University Hospital</i>			11:45	6:15	1:45	18:45		
12:11-12:36	Ultra-rapid genomic sequencing in the newborn Dr David DIMMOCK <i>Rady Children's Institute for Genomic Medicine</i>			12:11	6:41	2:11	19:11		
12:36-13:01	Ethical issues in genomic consent for high-risk patients Associate Professor Curtis COUGHLIN <i>University of Colorado School of Medicine</i>			12:36	7:06	2:36	19:36		
13:01-13:30	BREAK			13:01	7:31	3:01	20:01		
SPONSORED SYMPOSIUMS									
SYMPOSIUM HALL A				SYMPOSIUM HALL B					
13:30-14:30	Understanding ASDM from our experiences in Gaucher disease: from the science to the clinical practice Prof Pramod MISTRY, Dr Michel TCHAN, Prof Maurizio SCARPA Presented by Sanofi Genzyme 			Newborn Screening for Spinal Muscular Atrophy & Recommended Uniform Screening Panel in the US: from SCID to SMA, and beyond Veronica WILEY and Mei BAKER Presented by Perkin Elmer 		13:30	8:00	3:30	20:30
PARALLEL SESSIONS									
CONCURRENT HALL 1		CONCURRENT HALL 2		CONCURRENT HALL 3					
Fat Oxidation and GSD		Neurotransmitter disorders		Clinical Mitochondrial Disorders					
Restoration of interaction between FAO and ETC proteins in VLCAD and VLCAD-deficient mice mitochondria by addition of recombinant VLCAD Dr Yudong WANG		The first consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies Prof Thomas OPLADEN		Australian Childhood Mitochondrial Epidemiology Study- Preliminary Results Dr Carolyn BURSLE					
Novel mouse model of Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) retinopathy Mr Garen GASTON		A phase 1/2, open-label, randomized, intra-subject escalation study to evaluate the safety and efficacy of PTC923 in primary tetrahydrobiopterin deficient subjects with hyperphenylalaninemia Prof Nicola LONGO		A novel variant in CRLS1 is associated with fatal infantile cardiomyopathy, encephalopathy, sensorineural hearing loss, bull's eye maculopathy and nephrogenic diabetes insipidus Dr Shanti BALASUBRAMANIAM					
Preclinical evidence of efficacy of heptanoate and derivatives as anaplerotic therapy for medium-chain acyl-CoA dehydrogenase deficiency Prof Al-Walid MOHSEN		Evaluation of 3-O-methylidopa in dried blood spots for the diagnosis of aromatic L-amino-acid decarboxylase (AADC) deficiency in newborn screening and at-risk screening Prof Thomas OPLADEN		Clinical spectrum of F-box and Leucine-rich repeat protein 4 (FBXL4) related mitochondrial DNA Depletion Syndrome Dr Rachel WONG					
Genotype-phenotype correlations in CPT1A deficiency detected by newborn screening in Pacific populations Dr Isaac BERNHARDT		Interim Results of the Vigilant Observational Study: Clinical Characteristics of Creatine Transporter Deficiency Dr Judith MILLER		Mitochondrial DNA depletion syndromes: a case series of a single center experience Dr Tuğçe KURTARANER					
Sudden cardiac arrest in young adult patients with long-chain 3-hydroxyacyl CoA dehydrogenase (LCHAD) deficiency, a retrospective case series report Dr Gabriela ELIZONDO		Comprehensive insights expanding the phenotypic spectrum of inherited disorders of biogenic amines Dr Oya KUSEYRI HÜBSCHMANN		Characterisation of the neurological phenotype and long-term outcome of GLRX5 associated iron-sulfur cluster deficiency in four cases Dr Bindu Parayil SANKARAN					
Complications potentially associated with dietary management of Glycogen Storage Disease Type Ia (GSDIa) Dr Eliza KRUGER		Stem cell modelling of GTPCH deficiency in neural progenitor cells reveals changes in antioxidant capacity in affected cells Mrs Lena NEUMANN, Dr Sabine JUNG-KLAWITTER		An exercise intervention in children with mitochondrial skeletal muscle disorders Ms Nancy VAN DOORN					
16:00-16:30	NETWORKING AND TRIVIA BREAK			16:00	10:30	6:00	23:00		
PARALLEL SESSIONS									
CONCURRENT HALL 1		CONCURRENT HALL 2		CONCURRENT HALL 3					
Organic acidaemias		Laboratory LSDs		PKU and urea cycle disorders					
Spectrum and characterization of bi-allelic variants in MMAB causing cblB-type methylmalonic aciduria Dr Patrick FORNY		Newborn screening for LSDs in Brazil: Pilot Study Update Dr Francyne KUBASKI		Investigating the urinary metabolome in 48 phenylketonuria (PKU) patients by nuclear magnetic resonance (NMR) spectroscopy: association of genotype phenotype value (GPV) with metabolomic results. A/Prof Friedrich TREFZ					
Integrated multi-omic analysis of a rare inborn error of metabolism Dr Patrick FORNY		Neurofilament light chain and glial fibrillary acidic protein: reliable biomarkers in metachromatic leukodystrophy and the importance of paediatric reference values Ms Shanice BEERPOOT		Genotype-based phenotype prediction in phenylketonuria (PKU) patients Prof Nenad BLAU					
Protein load aggravates renal mitochondrial dysfunction in propionic aciduria Dr Anke SCHUMANN		Quantification of lysosphingomyelin and lysosphingomyelin-509 for the screening of acid sphingomyelinase deficiency Dr Francyne KUBASKI		Metabolic situation in 26 Chilean PKU adult with compliance and noncompliance treatment Dr María LEAL-WITT					
Persistent CSF biochemical abnormalities in transplanted patients with methylmalonic acidemia: a longitudinal study. Dr Diego MARTINELLI		Clinical phenotype and molecular analysis for 16 Cases of Galactosialidosis Dr Toko SHIBUYA		Increase in dietary phenylalanine tolerance following demonstrated response to Sapropterin testing – the Queensland experience of sapropterin-responsive children under 18 years with phenylketonuria Ms Aoife ELLIOTT					
Ethylmalonic acid impairs glutamate oxidation and induces mitochondrial permeability transition in rat cerebellum Prof Guilhian LEIPNITZ		Iduronate-2-sulfatase transport vehicle restores peripheral and central fluid biomarkers in a mouse model of Hunter Syndrome Dr Annie ARGUELLO		Efficacy and safety of the recommended pegvaliase dosing regimen in adults with phenylketonuria in the phase 3 PRISM studies Dr Stephanie SACHAROW					
Bezafibrate prevents redox and mitochondrial homeostasis deregulation in brain of glutaryl-CoA dehydrogenase deficient mice Prof Guilhian LEIPNITZ		Frequency of carriers for rare recessive Mendelian diseases in a Brazilian cohort of 320 patients Dr Caio Robledo QUAIO		Safety and efficacy of DTX301, an AAV8 gene therapy, in adults with late-onset ornithine transcarbamylase (OTC) deficiency: results from a phase 1/2 clinical trial Prof Cary O. HARDING					
DAY ONE CLOSE									
18:00-20:00	Welcome reception - In person Delegates only								

AEDT	MONDAY 22 NOVEMBER 2021			AEDT	IST	CET (Sunday)	CST (Sunday)
07:00-07:30	Online Q&A - New approaches to diagnosis Chaired by Eva Morava- Kozicz and Janice Fletcher			7:00	1:30	21:00	14:00
07:30-08:00	Online Q&A - Screening Chaired by Carmencita Padilla and Dianne Webster			07:30	2:00	21:30	14:30
NEW THERAPIES							
08:00-08:27	Liver targeted gene therapy - an explosion of possibilities Professor Ian E. ALEXANDER <i>Sydney Children's Hospital Network</i>			08:00	2:30	22:00	15:00
08:27-08:59	Treatment of metabolic disorders using genomic technologies Professor Charles VENDITTI <i>National Institutes of Health</i>			08:27	2:57	22:27	15:27
08:59-09:29	CNS targeted gene therapy: Update on gene therapy for lysosomal diseases Associate Professor Steven GRAY <i>University of Texas Southwestern Medical Center</i>			08:59	3:29	22:59	15:59
09:29-10:01	Novel approaches in treatment of CDG: Bringing therapies from bench to bedside Professor Eva MORAVA <i>Mayo Clinic School of Medicine</i>			09:29	3:59	23:29	16:29
10:01-10:20	POSTER VIEWING BREAK			10:01	4:31	0:01 (Monday)	17:01
10:20-10:45	NETWORKING AND TRIVIA BREAK			10:20	4:50	0:20	17:20
ALLIED HEALTH		ADULT METABOLIC		LABORATORY			
CONCURRENT HALL 1		CONCURRENT HALL 2		CONCURRENT HALL 3			
Management of GSD, where are we now and where are we heading Prof Priya KISHANI		Competencies in adult metabolic medicine Dr Sandra SIRRS, Dr Annalisa SECHI		Improving diagnosis and screening: biochemical assays versus genomic applications Prof Maria FULLER			
Centre based approach to the management of hepatic GSD Miss Gemma HACK, Ms Joanna GRIBBEN		Late-onset Pompe Disease: a systematic review and meta-analysis Dr Ida Vanessa SCHWARTZ		Safety of home-based infusion of alglucosidase alfa in late-onset Pompe disease: 13 years of experience from the Erasmus MC university medical center Miss Imke DITTERS			
Center based approach of the management of hepatic GSD Mrs Foekje DE BOER, Mrs Caroline VAN DER SCHAAF		Natural history and complications of hereditary fructose intolerance in adult patients. Dr Nour ELKHATEEB		Advancing the quality of diagnostic testing for inherited Metabolic Diseases – the role of ERNDIM EQA schemes Dr George RUIJTER, Dr Joanne CROFT			
Living with a chronic disease and maintaining quality of life Dr Laura SMITH		New condition-specific protein substitutes demonstrate good acceptability with improved compliance, stable tolerance and metabolic control in children and adults with HCU, MSUD and TYR Ms Diane GREEN		Laboratory experience in diagnosing galactosialidosis using matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) and post analytical pattern recognition software Ms Gisele PINO			
Role of continuous glucose monitoring in personalized glycemic management of hepatic glycogen storage disorders Dr Ambika GUPTA, Dr Neerja GUPTA		Use Of SglT2 In Neutropenia In Gsd 1b, A UK Experience Mr Antonio OCHOA		IEMbase: An online knowledge base and mini-expert tool for the diagnosis of inborn errors of metabolism Prof Nenad BLAU			
Hepatocellular adenoma development in glycogen storage disease type Ia patients is associated with G6PC1 genotype and sex: a nationwide observational cohort study. Mr Fabian PEEKS		Nutritional adequacy of low protein diets in a sample of adult patients with Inborn Errors of Intermediary Protein Metabolism Dr Nicola VITTURI		Laboratory experience in diagnosing galactosialidosis using matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) and post analytical pattern recognition software Ms Gisele PINO			
The impact on the family and child pre and post-transplant Mrs Julia		Role of GLA variants in Parkinson's Disease Dr Merve KOÇ YEKEDÜZ		Solving the unsolved: Implementing new -Omics approaches to enable diagnosis of virtually all patients with mitochondrial disease Ms Sumudu AMARASEKERA			
				Plasma C24:0 and C26:0 lysophosphatidylcholines are reliable biomarkers for the diagnosis of peroxisomal β -oxidation disorders. Mr Blai MORALES-ROMERO			
				DNLS10 corrects lysosomal lipid accumulation and biomarkers of skeletal dysplasia in patients with neuronopathic MPS II: An exploratory analysis of fluid-based biomarkers Dr Akhil BHALLA			
13:15-13:30	BREAK			13:15	7:45	3:15	20:15
SPONSORED SYMPOSIUM							
SYMPOSIUM HALL A				SYMPOSIUM HALL B			
Diagnose. Understand. Treat. A Glance at a Global NPC Cohort Prof. Peter BAUER M.D Presented by Centogene				Expediting diagnosis in rare metabolic diseases – examples from neuronal ceroid lipofuscinosis type 2 (CLN2) and mucopolysaccharidosis (MPS) Dr Carolina FISCHINGER, Dr D. Scott Thomas DEMAREST, Dr Cathleen Louise RAGGIO Presented by BioMarin <i>*Restricted to Health Care Professionals only - This sessions is not intended for US Healthcare Professionals</i>			
							
PARALLEL SESSIONS							
CONCURRENT HALL 1		CONCURRENT HALL 2		CONCURRENT HALL 3			
LSD Therapeutics		Novel Therapeutics and Mechanisms		Disease Mechanisms			
Sebelipase alfa enzyme replacement therapy in Wolman disease allows long-term survival with high health-related quality of life in a retrospective study with up to ten years follow-up Dr Tanguy DEMARET		Discovery of CDX-6512, a gastrointestinal-stable methionine-gamma-lyase as a potential orally-administered enzyme therapy for homocystinuria Dr Kristen SKVORAK		Dominant variants at the catalytic site of STT3A result in a CDG with a variable phenotype including intellectual disability, dysmorphic symptoms, short stature, skeletal dysplasia and cramps Dr Matthew WILSON			
Switching from agalsidase alfa to pegunigalsidase alfa to treat patients with Fabry disease: 1 year of treatment data from BRIDGE, a phase 3 open-label study Prof Ales LINHART		Discovery of a gastrointestinal-stable bacterial leucine decarboxylase as a potential orally-administered enzyme therapy for maple syrup urine disease Dr Kristen SKVORAK		Gm3 synthase deficiency is associated with increased mitochondrial respiration in the brain Dr Eric GOETZMAN			
Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: A study of the European Pompe Consortium. Miss Imke DITTERS		Allosteric, specific GALK1 inhibitors for development as substrate reduction therapy for classic galactosemia. Dr Sabrina MACKINNON		Abnormalities of Mitochondrial Dynamics and Bioenergetics in Neuronal Cells from CDKL5 Deficiency Disorder Dr Nicole VAN BERGEN			
Nature history of CNS manifestation of infantile onset Pompe disease: a prospective cohort observational study using a quantitative scoring to reveal the progressive evolution of white matter changes Dr Wen-Chin WENG		Patient characteristics in the pivotal phase 3 PEACE trial of pegzilarginase human enzyme therapy for Arginase 1 Deficiency Dr George DIAZ		Impaired cofactor-dependent maturation of mitochondrial sulfite oxidase represents a new class of sulfite oxidase deficiency Prof Guenter SCHWARZ			
Structure of Human Muscle Glycogen Synthase Guides Inhibitor design for Pompe Disease Dr Thomas MCCORVIE		Association between early treatment and neurodevelopmental outcome in 18 families with PDE-ALDH7A1 Prof Clara VAN KARNEBEEK		Loss of function of the phosphoinositide kinase PI4KA causes hypomyelinating leukodystrophy Prof Aurora PUJOL			
Venglustat Pharmacokinetics (PK) and Biomarker Responses in Patients with Gaucher Disease Type 3 or GBA-associated Parkinson Disease Dr M. Judith PETERSCHMITT		Correction of mitochondrial dysfunction in ataxia-telangiectasia (A-T): an anaplerotic approach to therapy Prof David COMAN		Early prediction of disease severity in cytosolic Urea Cycle Disorders Dr Matthias ZIELONKA			
16:00-16:15	REFRESH BREAK			16:00	10:30	6:00	23:00
16:15-17:00	Garrod Lecture Simplifying the clinical classification of polymerase gamma (POLG) disease based on age of onset; studies using a cohort of 155 cases Dr Laurence BINDOFF			16:15	10:45	6:15	23:15
SPONSORED SYMPOSIUM							
SYMPOSIUM HALL A		SYMPOSIUM HALL B		SYMPOSIUM HALL C		SYMPOSIUM HALL D	
Rare neurometabolic disorders: A focus on AADC deficiency Dr. Wuh-Liang Hwu, Prof. Thomas Opladen, Prof. Agathe Roubertie Presented by PTC Therapeutics <i>*restricted to Health Care Professionals only</i>		20 years of the Fabry Outcome Survey: understanding the importance of organ protection in patients with Fabry disease Prof. Kathy Nicholls, Prof. Ales Linhart, Prof. Christoph Kampmann, Ms. Mary Pavlou Presented by Takeda <i>*restricted to Health Care Professionals only</i>		Translating theory into practice in Fabry disease: evidence from clinical trials to real-world Dr Michel Tchan, Professor Daniel Bichet, Professor Roser Torra Presented by Amicus Therapeutics <i>*restricted to Health Care Professionals only - This sessions is not intended for US Healthcare Professionals</i>		Pursuing More Effective Diagnosis and Treatment of Pompe Disease: Applying New Advances into Practice Priya S. Kishnani, David Kronn, Kenneth I. Berger Presented by Sanofi Genzyme	
							
CLOSE OF DAY TWO							

AEDT	TUESDAY 23 NOVEMBER 2021			AEDT	IST	CET (Monday)	CST (Monday)
07:00-07:30	Online Q&A - New therapies Chaired by John Christodoulou and Roberto Guigliani			07:00	1:30	21:00	14:00
07:30-08:00	Online Q&A - Allied health Chaired by Anita Inwood and Rebecca Halligan	Online Q&A - Adult metabolic Chaired by Michel Tchan and Yusuf Rahman	Online Q&A - Laboratory Chaired by Veronica Wiley and Advije Tolun	07:30	2:00	21:30	14:30
INTEGRATED CARE							
08:00-08:05	The patient experience of research Mrs Sarah King			08:00	2:30	22:00	15:00
08:05-08:34	Patient advocacy in guiding policy development for metabolic disorders Nicole Mills Rare Voices Australia <i>* This presentation is supported by Menarini</i>			08:05	2:35	22:05	15:05
08:34-09:02	Design and outcome of Rare Disease Registries in PKU Dr Susan Berry University of Minnesota			08:34	3:04	22:34	15:34
09:02-09:28	Consumer consultation to provide focused family centered-care Dr Terry Derks University of Groningen, Beatrix Children's Hospital			09:02	3:32	23:02	16:02
09:28-10:00	Treatment of the rare and Indigenous Dr Callum Wilson National Metabolic Service, Starship Children's Hospital			09:28	3:58	23:28	16:28
10:00-10:20	POSTER VIEWING BREAK			10:00	4:30	0:00 (Tuesday)	17:00
10:20-10:42	NETWORKING AND TRIVIA BREAK			10:20	4:50	0:20	17:20
LATE BREAKING NEWS							
10:42-11:45	Long-term functional correction of cystathionine beta-synthase deficiency in mice by adeno-associated viral gene therapy Prof Warren Kruger			10:42	5:12	0:42	17:42
	Mini-COMET: Safety and efficacy after ≥97 weeks' avalglucosidase alfa in infantile-onset Pompe disease (IOPD) patients previously treated with alglucosidase alfa who had demonstrated clinical decline Dr David Kronn						
	Phenylbutyrate Reduces Metabolite Accumulation and Improves Bioenergetics in Combined D,L-2-Hydroxyglutaric Aciduria Dr Yu Leng Phua						
	Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria with Live Bacterial Therapeutic SYN1618 Prof Jerry Vockley						
PARALLEL SESSIONS							
LSD Therapeutics		Vitamins and Cofactors		General Metabolism			
Two-year outcomes of the first trial of olipudase alfa enzyme replacement therapy in children with chronic acid sphingomyelinase deficiency show continued improvements in clinical parameters Prof Roberto GIUGLIANI		Complications, Hospital Admissions, and Healthcare Costs During Pharmacologic Treatment For Wilson Disease Dr Eliza KRUGER		The Impact of SARS-CoV2 infection on paediatric patients with Inherited Metabolic Diseases in the UK: The first 14 months. Dr Sarah HULLEY			
Olipudase alfa enzyme replacement therapy improves liver and lipid parameters in adults and children with chronic acid sphingomyelinase deficiency: 1-year results of the ASCEND and ASCEND-Peds trials Prof Maurizio SCARPA		Identification of novel pathogenic MOC51 variants predicts molybdenum cofactor deficiency type A disease incidence Prof Guenter SCHWARZ		Treatable Inherited Metabolic Disorders causing Intellectual Disability: 2021 Review and App. Prof Clara VAN KARNEBEEK			
Ex vivo autologous haematopoietic stem cell gene therapy in mucopolysaccharidosis type IIIA Dr Simon JONES		Increased Survival in MoCD Type A Patients Treated with Fosdenopterin when Compared to a Natural History Cohort Dr Liza SQUIRES		CAMLG-CDG: a novel glycosylation and membrane trafficking defect Dr Matthew WILSON			
Interim Results of Transpher A, a Multicentre, Single-Dose, Phase 1/2 Clinical Trial of ABO-102 Gene Therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA) Dr Nicholas SMITH		5,10-methylenetetrahydrofolate synthetase (MTHFS) deficiency: an extreme rare defect of folate metabolism. Prof Henk BLOM		Decipher N-linked glycosylation changes in the plasma from CDG patients Dr Miao HE			
RGX-121 gene therapy for the treatment of severe mucopolysaccharidosis type II (MPS II): Interim analysis of data from the first in human study Prof Roberto GIUGLIANI		Eladocogene Exuparvec: Gene Therapy Improves Motor Development in Patients With Aromatic L-Amino Acid Decarboxylase Deficiency Dr Paul W-L HWU		De novo DHDDS variants cause a neurodevelopmental and neurodegenerative disorder in the spectrum of myoclonus syndromes intersecting glycosylation and organelle disorders Dr Serena SERENA GALOSI			
Clinical data trends from Phase 1 and Phase 2 studies for AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease Prof Mark THOMAS		Eladocogene Exuparvec Improves Body Weight and Reduces Respiratory Infections in Patients With Aromatic L-Amino Acid Decarboxylase Deficiency Dr Paul W-L HWU		Identification of the first patient with Guanidinoacetate Methyltransferase Deficiency by newborn screening. Prof Marzia PASQUALI			
13:15-13:30	BREAK			13:15	7:45	3:15	20:15
SPONSORED SYMPOSIUM							
SYMPOSIUM HALL A		SYMPOSIUM HALL B		SYMPOSIUM HALL C			
Advancing the patient experience during ex vivo lentiviral gene therapy for lysosomal disorders Dr. Robert Wynn, Dr. Chris Mason, Dr. Mark Thomas, Dr. Kathleen Nicholls, Dr. Ben Carnley Presented by Avrobio <i>*restricted to Health Care Professionals only</i>		Targeting Toxic Galactitol for the Treatment of Classic Galactosemia Shoshana Shendelman, Laura Saltontall, Riccardo Perfetti Presented by Applied Therapeutics		A tale of two Phe states: PKU neurocognitive burden and the Palynziq experience Mark Walterfang, Cary Harding Symposium sponsored and funded by BioMarin <i>*restricted to Health Care Professionals only - This sessions is not intended for US Healthcare Professionals</i>			
SPECIAL AWARD PRESENTATIONS							
Long-term, sustained efficacy and safety from a phase 1/2 clinical trial of an AAV8-mediated liver-directed gene therapy in adults with glycogen storage disease type Ia. Dr Terry G. J. Derks							
Nanoparticles with β-cyclodextrin as a technological advantage to Niemann-Pick C treatment: preliminary results of biodistribution and cholesterol reduction Dr Carmen Regla Vargas							
The Australian Genomic Health Alliance (AGHA) Mitochondrial Flagship: Delivering Mitochondrial Diagnoses at a National Level. Prof John Christodoulou							
A systematic study of a panel of mitochondrial functional testing in fibroblasts shows strong clinical utility Prof Johan Van Hove							
15:30-16:20	Danks Lecture Transforming Rare Disorders Introduction by: Jim McGill Award Recipient: John Christodoulou			15:30	10:00	5:30	22:30
16:20-16:30	REFRESH BREAK			16:20	10:50	6:20	23:20
SPONSORED SYMPOSIUM							
SYMPOSIUM HALL A		SYMPOSIUM HALL B		SYMPOSIUM HALL C		SYMPOSIUM HALL D	
Introducing HST5040: A Systemic Small Molecule Approach for MMA and PA Carlo Dionisi-Vici, Kimberly A Chapman, Gerald F. Cox Presented by Hemoshear <i>*restricted to Health Care Professionals only</i>		The story of the United Kingdom National Alkaptonuria (AKU) Centre and its global influence on research, changing the face of AKU management. Shirley Judd, Prof Lakshminarayan Ranganath Presented by VitaFlo		Burden of treatment and Quality of Life in Patients with Urea Cycle Disorders Karolina Stepien, Francis Fatoye, Gillian Yeowell, Danielle Burns Presented by Immedica <i>*restricted to Health Care Professionals only</i>		Glucosylceramide Synthase Inhibition and its Critical Role in the Glycosphingolipid Hub of Lysosomal Storage Disorders Associate Professor Carolyn Ellaway, Professor Tim Cox, Professor Hans Aerts Presented by Sanofi Genzyme	
CLOSE OF DAY THREE							
19:00-00:00	<i>Conference Dinner - In person registrations only</i>						

14th International Congress of Inborn Errors of Metabolism 2021



'Transforming Rare Disorders'

21-24 November 2021



AEDT	WEDNESDAY 24 NOVEMBER 2021	AEDT	IST	CET (Tuesday)	CST (Tuesday)
07:30-08:00	Online Q&A - Late Breaking news Chaired by Kimitoshi Nakamura and Jim Bonham	07:30	2:00	21:30	14:30
08:00-08:30	Online Q&A - Special award presentations Chaired by Ute Spiekeroetter and Shawn McCandless	08:00	2:30	22:00	15:00
08:30-09:00	Online Q&A - Integrated care Jose Abdenur and Anita Inwood	08:30	3:00	22:30	15:30
09:00-09:30	Society Updates SIMD - Gerry Berry SLEIMPN - Ceila Perez de Ferrán SSIEM - Gajja Salomons and Ute Spiekeroetter ASIEEM - Veronica Wiley Presentation for ICIEM 2025 JSIMD - Kimitoshi Nakamura Congress Close Kaustuv Bhattacharya	09:00	3:30	23:00	16:00



14TH INTERNATIONAL CONGRESS OF
INBORN ERRORS OF METABOLISM

VALUED MAJOR PARTNERS

OPAL PARTNERS



PLATINUM PARTNERS



GOLD PARTNERS



SILVER PARTNERS



BRONZE PARTNERS



PROGRAM PARTNERS

